Vaccine maker BioNTech to use mRNA tech to target malaria
The Germany-based company, which developed the first widely approved coronavirus shot together with U.S. partner Pfizer, aims to begin clinical trials for a "safe and highly effective malaria vaccine'' by the end of 2022.